MYD88 and neoplasm: Nevertheless, further studies are needed to better understand the functional properties of MYD88L265P-specific T cells in the tumor niche, identify specific major histocompatibility complex haplotypes for TCRs that could be used for immunotherapy, and quantify the extent to which mutant MyD88 is a target of specific immunity [118,119].